AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Patients & Family

Font Size:

	The AlloMap Testing Process
	Patient Service Centers
	Health Insurance
	Terms To Know
	FAQ

Presenting AlloMap Molecular Expression Testing

An Easy Way to Check Your New Heart for Rejection

FOR PATIENT PURPOSES ONLY:

This description of AlloMap testing is not intended to provide clinical guidance. Use of AlloMap testing is at the sole discretion of your physician. Ask your physician if AlloMap testing is appropriate for your care.

The Advantages of Non-invasive AlloMap Testing
Until now, doctors monitored for signs of organ rejection by using invasive tissue biopsies that collect samples directly from the heart. Biopsies are time-consuming and may be uncomfortable—and they can involve the added risks of infection, heart valve damage and heart puncture.

Presenting a convenient and effective alternative to biopsies: AlloMap molecular expression testing. All you need for AlloMap testing is a simple blood sample that can be drawn at your transplant center. Your doctor will determine if AlloMap testing is right for you--and whether it will be used either alone or in combination with other diagnostic tools like biopsy. Click here for more on the AlloMap testing process.

Since January 2005, the XDx Reference Laboratory has provided AlloMap molecular expression testing for patients with heart transplants. This safe, convenient and reliable testing process is a breakthrough in determining the risk of rejection in patients 15 years or older who have had a heart transplant more than 2 months ago. AlloMap testing is being used at many United States transplant centers as a non-invasive method to monitor heart transplant patients for rejection. AlloMap testing is currently only available in the United States.

Using a simple blood sample, AlloMap testing detects the absence of rejection of your new heart by looking at certain genes in your white blood cells. When these genes turn on or off (called "gene expression"), your white blood cells respond by either quieting down or increasing their activities—which can cause rejection. Based on your AlloMap test score, your physician can monitor and manage your progress after your transplant to determine that you are not rejecting your heart. Click here to learn about the importance of rejection monitoring.

Why rejection monitoring is important to your new heart

It is very important for you and your doctor to know if your immune system is trying to reject your heart. Your immune system includes white blood cells that move within your bloodstream to ensure good health. These cells are always on the lookout for bacteria, viruses, and other foreign agents that might make you sick.

After a transplant, your white blood cells see your new heart as a foreign object. Rejection occurs when white blood cells attack your new heart. If rejection continues, it can actually damage or destroy your new heart.

Ask your doctor if AlloMap molecular testing is right for you. Click here for answers to questions frequently asked by patients. For details on the AlloMap testing process, click here.

Find out more:

	The AlloMap Testing Process
	Patient Service Centers
	Health Insurance
	Term To Know
	FAQ

Related Links
	News
	Links